Overview

Efficacy and Safety of Opicapone in Clinical Practice

Status:
Completed
Trial end date:
2018-07-04
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the change in subject's condition according to the Investigator's Global Assessment of Change after three months of treatment with 50 mg opicapone once daily in a heterogeneous patient population reflecting daily clinical practice.
Phase:
Phase 4
Details
Lead Sponsor:
Bial - Portela C S.A.
Treatments:
Aromatic Amino Acid Decarboxylase Inhibitors
Dopa Decarboxylase
Levodopa
Opicapone